Haleon plc Reports Share Transaction on Sept 25, 2025

TL;DR

Haleon bought back its own shares on 9/25/25. Details in 6-K.

AI Summary

Haleon plc announced a transaction in its own shares on September 25, 2025. The company, formerly known as DRVW 2022 Ltd, is a foreign private issuer filing a Form 6-K report. This filing details the company's activities related to its share transactions.

Why It Matters

This filing provides insight into Haleon's capital management activities, which can affect share price and investor perception.

Risk Assessment

Risk Level: low — The filing is a routine report of share transactions and does not indicate any significant new risks.

Key Players & Entities

• Haleon plc (company) — Registrant
• DRVW 2022 Ltd (company) — Former name of registrant
• September 25, 2025 (date) — Date of share transaction and filing

FAQ

Filing Documents

• a7088a.htm (6-K) — 34KB
• a7088a000.jpg (GRAPHIC) — 3KB
• 0001654954-25-011080.txt ( ) — 40KB

From the Filing

IN OWN SHARES a7088a   UNITED STATES   SECURITIES AND EXCHANGE COMMISSION   Washington, D.C. 20549     FORM 6-K   REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934   For the month of September 2025   Commission File Number: 001-41411   Haleon plc (Translation of registrant’s name into English)   Building 5, First Floor, The Heights, Weybridge, Surrey, KT13 0NY (Address of principal executive offices)     Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:     Form 20-F ☒   Form 40-F ☐       EXHIBIT INDEX   Exhibit Number Description 99.1 25 September 2025 - “Transaction in Own Shares”   99.1       Haleon plc:   Transaction in own shares   25 September 2025:   Haleon plc (the "Company" or "Haleon") today announces   the purchase of 3,251,858 ordinary shares of £0.01 each in the Company (the "Shares")   under the second tranche of its share buyback programme announced on 31 July 2025.     London Stock Exchange CBOE (UK)/BXE CBOE (UK)/CXE Date of purchase: 24 September 2025 24 September 2025 24 September 2025 Number of Shares purchased: 3,101,999 149,859 - Highest price paid per Share (p): 332.4000 332.3000 - Lowest price paid per Share (p): 327.6000 327.7000 - Volume weighted average price paid per Share (p): 330.4723 330.2795 -   The Company intends to hold the purchased shares as treasury shares.   Following the settlement of the above, the Company's registered share capital   is 8,952,353,648 ordinary shares of £0.01 each, of which 36,589,403 are held as treasury shares.   Therefore, the number of ordinary shares with voting rights is 8,915,764,245 and   this figure may be used by shareholders to determine if they are required to notify their interest, or a change to their interest, in Haleon under the FCA's Disclosure Guidance and Transparency Rules.   In accordance with Article 5(1)(b) of Regulation (EU) No 596/2014 as it applies in the UK (the Market Abuse Regulation), a full breakdown of the individual trades is available at the link below:   http://www.rns-pdf.londonstockexchange.com/rns/7050A_1-2025-9-24.pdf   This announcement does not constitute, or form part of, an offer or any solicitation of an offer for securities in any jurisdiction.   This announcement and individual trade breakdown will also be available on the Company's website at:   www.haleon.com/investors .   Enquiries     Investors Media   Jo Russell   +44 7787 392441 Zoë   Bird +44 7736 746167 Rakesh Patel      +44 7552 484646 Victoria Durman +44 7894 505730 Email:   investor-relations@haleon.com Email:   corporate.media@haleon.com   About Haleon Haleon (LSE/NYSE: HLN) is a global leader in consumer health, with a purpose to deliver better everyday health with humanity. Haleon's product portfolio spans six major categories - Oral Health, Vitamins, Minerals and Supplements (VMS), Pain Relief, Respiratory Health, Digestive Health and Therapeutic Skin Health and Other. Its long-standing brands - such as  Advil, Centrum, Otrivin, Panadol, parodontax, Polident, Sensodyne, Theraflu  and  Voltaren  - are built on trusted science, innovation and deep human understanding.   For more information, please visit   www.haleon.com .              SIGNATURE       Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.       HALEON PLC (Registrant)   Date: September 25, 2025 By: /s/ Amanda Mellor     Name: Amanda Mellor     Title: Company Secretary

View Full Filing

View this 6-K filing on SEC EDGAR